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ABSTRACT
This study involved long-term analysis of children and
adolescents with house dust mite sensitive allergic
asthma to investigate the effect of immunotherapy
(IT) with a house dust extract containing certain
amounts of Dermatophagoides farinae (Der f7), and
Dermatophagoides pteronyssinus (Der p 1, Der p2).
The medication requirements, peak expiratory flow
(PEF) circadian variations, forced expiratory flow bet-
ween 25 and 75% of the vital capacity (FEF2S-7S) ,
maximal expiratory flow at 50 and 25% vital capacity
(Vso and V2S) , and specific airway resistance (SRaw)
were evaluated over a 3-year period in patients trea-
ted with IT. When compared with the results for control
asthmatic patients who had not been treated with IT,
statistically significant amelioration regarding the PEF
circadian variations, %FEF2S-7S, %Vsoand %V2Swas obser-
ved in IT-treated patients during the study. Although
the improvement for medication requirement during
the study was not different statistically between the two
groups, we concluded that long-term house dust IT
may result in amelioration of pulmonary functions,
which may account for its clinical effectiveness in the
treatment of asthmatic patients.
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INTRODUCTION
Asthma is a multifactorial disease, and many triggering
factors have been identified. Among the triggering fac-
tors, allergy appears to be more prevalent than previously
believed,' and house dust mites represent one of the
major allergens throughout the world. Immunotherapy
(IT) or allergen-specific hyposensitization has been per-
formed for the treatment of allergic diseases since it was
introduced by Noon and Cantar in 1911.2 Although IT
with a house dust extract is generally accepted as being
efficient in appropriate circurnstonces.P" it is still debat-
able whether this treatment affects the natural history of
bronchial asthmaJ,8 In most studies, the efficacy of the
treatment was judged after relatively short-term obser-
vation, and the studies on the mechanisms underlying IT
have been focused on the alteration of the immuno-
logical stotus."" The respiratory physiology of asthmatic
individuals is of great practical importance but to date
has not been examined fully in IT-treated childhood
patients through a long-term study. In this study we con-
ducted a clinical trial of IT over a 3-year period in
children and adolescents with bronchial asthma. Multiple
indices of the asthma severity, including pulmonary func-
tion test results, were recorded.
METHODS
Patients
A total of 27 patients, who met the diagnostic criteria of
the Guidelines for the Diagnosis and Management of
Bronchial Asthma of the Japanese Society of Aller-
gology,13 participated in this study. All the patients were
sensitive to house dust mites, according to the skin prick
test reactivity and mite-specific IgE serum level. Before
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Table 1. Patient characteristics
Male/female
Age (years)
IgE (IU/mL)
Dp-lgE (UA/mL)
Control medication
Inhaled beclomethasone
Cromolyn and theophylline
With immunotherapy
-------
7/4
11.5 ± 4.0*
794,316-1,995**
79,40-158
5
6
Without immunotherapy
7/4
10.5±3.9
631,316-1,259
50,16-158
5
6
*Mean ± 1 standard deviation. **Geometric means and 1 SO range.
the study informed consent was obtained from the sub-
jects and/or their parents. A total of 13 patients were
started on IT with a house dust extract, the others being
treated symptomatically. Two of the 13 IT-treated patients
and three of the 14 IT-nontreated patients were elimi-
nated from the study because of their failure to complete
the protocol. The characteristics of the 11 IT-treated
patients, aged 6-18 years, and the 11 IT-nontreated
patients, aged 8-19 years, who completed the study over
the 3-year period are summarized in Table 1.
Immunotherapy
We used a standardized extract of house dust containing
certain amounts of Der f1 , Der p 7 and Der p2 (Torii Phar-
maceutical Co., Tokyo, Jopcn}." Immunotherapy was
performed according to the rush protocol, originally des-
cribed by Miller and Mansmann,15 as shown in Table 2.
During the rush IT, each patient was hospitalized and
given ketotifen twice a day, with inhalation of sodium
cromoglycate plus procaterol four times a day together
with their controller medications for asthma. While
patients were being given injections, peak expiratory flow
(PEF) was determined 30 min after each shot for all the
patients. The dosage increment was not made when the
local induration exceeded 3 cm in diameter, or when the
PEF result was less than 50% of the personal best value.
No major problems were encountered in any patient,
with the exception of one who developed chest tightness,
wheezy coughing, bloody sputum and generalized urti-
caria within 20 min of receiving an injection of 0.1 mL of
1:10 w/v house dust extract. After the rush IT, an injection
of the maintenance dose was given every second week
for 1 year, and then every month over the next 2 years at
the outpatient clinic of Kumamoto University Hospital,
Kumamoto. The adverse reactions and the maintenance
dosages are summarized in Table 3.
Table2. Rush injection protocol with a house dust extract
Dose (w/v) Day Dosage (mL) Time (h)
--- --_. - -- --
1-100000 1 0.05 11:00
0.10 13:00
0.20 15:00
0.35 17:00
2 0.50 09:00
1-10000 0.05 11:00
0.10 13:00
0.20 15:00
0.35 17:00
3 0.50 09:00
1-1000 0.05 11:00
0.10 13:00
0.20 15:00
0.35 17:00
4 0.50 09:00
1-100 0.05 11:00
0.10 13:00
0.20 15:00
0.35 17:00
5 0.50 09:00
1-10 0.05 11:00
0.10 13:00
0.15 15:00
0.20 17:00
Clinic visits
Clinic visits were designed to facilitate optimal asthma
control and close follow-up over an extended period of
time. Patient compliance with the prescribed medication
regimens was assessed by performing periodic pill counts,
and canister weight and serum theophylline measure-
ments. Medication was adjusted with the use of an
algorithm based on the clinical symptoms and daily PEF
values. The algorithm was designed to reduce medication
use to the lowest level that maintained stability. Thus, the
asthma disease activity was evaluated using daily medi-
cation usage scores (Table 4) as described by Gern et a/. 16
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Table 3. The adverse reactions and maintenance dosages for rush immunotherapy with a house dust extract in patients with
bronchial asthma
Case age/sex Final dose/adverse reaction Maintenance dosage
KM
OK
KS
TK
IA
YU
MU
MN
HN
UY
IA
14/F
17/F
15/M
14/M
9/F
10/M
8/M
6/M
8/M
8/M
18/F
10-2*,0.5 cc/induration > 3 cm
10-2,0.5 cc/locol urticaria
10- 1, 0.2 cc/systemic reaction
10-1,O.2cc
10-3, 0.5 cc/induration > 3 cm
10-2,0.35 cc/induration > 3 cm
10-2, 0.25 cc/induration > 3 cm
10-2, 0.25 cc/induration > 3 cm
10- 1, 0.15 cc/locol urticaria
10- 1, 0.25 cc/decreased PEF
10-2 , 0.35 cc/induration > 3 cm
10-2,0.3 cc
10-2,0.2 cc
10-2, 0.2 cc
10-1,0.2 cc
10-3, 0.3 cc
10-2, 0.2 cc
10-2, O. 15 cc
10-2, O. 15 cc
10-1,0.1 cc
10-1,0.1 cc
10-2 , 0.2 cc
*weight byvolume; PEF, peak expiratory flow.
Table 4. Daily medication usage scores
Medication Consumption Score
Cromolyn 1
Ketotifen 1
Theophylline 2
Inhaled ~-agonist 2
Inhaled beclomethasone < 400 ~g 2
< 400 ~g 3
Oral steroids 4
Immunotherapy (-I
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RESULTS
Statistical analysis
Serum total IgE (IU/mL) and Der p-specific IgE (O.p-lgE,
UA/mL) were analyzed as exponential values. The data
were expressed as geometric means and 1 standard devi-
ation (SO) range. Statistical analysis was performed by
means of Student's t-test for paired and unpaired com-
parisons. A probability (P) value of less than 0.05 was
considered significant.
Pulmonary function testing
Peak expiratory flow was measured by patients at home
with an Assess Peakflow Meter (Healthscan Products Inc.,
Cedar Grove, NJ, USA). The best of three attempts was
recorded in a diary twice daily, once in the morning before
the use of any bronchodilator and once in the evening
before bedtime medications were taken. The mean diurnal
variation was calculated with the following formula
(highest -lowest reading/mean reading of the day) X 100.
The FEF2s_7s, Vso, V2sand SRawwere measured with a body
plethysmograph (Minato-Ikagaku, Osaka, Japan). FEF2s_
75, Vso and V2s data were expressed as percentages
predicted for age and height of Japanese people.!"
The patients included in the two groups were similar in terms
of mean age, sex, IgE, Dp-specific IgE and requirement for
control medication (Table 1). The daily medication usage
scores before the study were 4.3 ± 1.5 for the IT-treated
group and 3.6 ± 1.6 for the IT-nontreated group, these two
scores not being different statistically (P > 0.3). After the 3-
year study, a statistically significant decrease was observed
Fig. 1 Changes in peak expiratory flow (PEF) circadian varia-
tion (%) after 3-year treatment period with or without
immunotherapy (IT) in patients with bronchial asthma. The PEF
circadian variations in a 4-week period were improved signifi-
cantly in both groups; however, the improvement rates in the
IT-treated group were significantly better than in the IT-non-
treated group.
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Fig. 2 Changes in percent-
age predicted FEF2S. 7S, Vso, V2S
and SRawafter 3-year treatment
period (a) with (n=8) or (b)
without (n=8) immunotherapy
in patients with bronchial
asthma. *NS, not significant.
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in both groups (i.e. improvement to 3.1 ± 3.4 (P < 0.05)
in the IT-treated group and to 2.5 ± 2.3 (P < 0.02) in the
IT-nontreated group). However, these improvements were
almost the same in the two groups (P > 0.5).
The PEF data for 2 patients in the IT-treated group
were omitted in this study, because their daily records
were not of sufficient quality to be analyzed. The means
and 1 SD of the PEF circadian variations for 4 weeks
before the protocol began were 27.9 ± 8.8% in the IT-
treated group and 18.6 ± 9.4% in the IT-
nontreated group, these two values being different sta-
tistically (P < 0.01). Although the PEF variations in a
4-week period in the IT-treated group had decreased
to 23.7 ± 10.9% after the 1-year therapy and to
22.0 ± 9.9% after the 2-year therapy, the ameliora-
tions were not significant statistically when compared
with the PEF variations before the therapy (P > 0.05
for both groups). The PEF variations had also
decreased to 17.5 ± 8.5% after the 1-year study and
to 15.5 ± 6.8% after the 2-year study in the IT-non-
treated group. However, the improvements were not
significant statistically when compared with the PEF
variations before the protocol began (P > 0.5 after
1 year of the study and P > 0.1 after 2 years of the
study). After the 3-year study had been completed, the
PEF circadian variations in a 4-week period were
improved significantly in both groups, becoming
14.9 ± 6.8% (P < 0.02) in the IT-treated group and
13.3 ± 6.6% (P < 0.05) in the IT-nontreated group.
As shown in Fig. 1, the improvement rates in the
IT-treated group were significantly better than those in
the IT-nontreated group (P < 0.05).
The data obtained using a body plethysmograph in the
subjects younger than 8 years were not always constant;
therefore, 3 of the IT-treated group and 3 of the IT-
nontreated group were excluded from the analysis. The
%FEF2S_7S, %VSO,%V2S and SRawfor the two groups were not
different statistically before the study (%FEF2S-7S, P > 0.2;
%Vso, P > 0.3; %V2S, P > 0.1; and SRaw, P > 0.2). Signifi-
cant ameliorations in %FEF2S-7S, %Vso, %V2S and SRawwere
not found in either group after the 1-year study or after the
2-year study. However, after 3 years of the study, %FEF2S-7S,
%Vsoand %V2S were significantly improved in the IT-treated
group, as shown in Fig. 2. In comparison, after 3 years
of the study these values slightly, but not significantly,
improved in the IT-nontreated group (%FEF2S-7S, P > 0.05;
%Vso, P > 0.2; and %V2S, P > 0.05). When SRaw was
compared between the baseline and after the 3-year study,
differences were not observed statistically in either group
(P > 0.05 for both groups) (Fig. 2).
DISCUSSION
Allergen avoidance is always the first recommendation
in the management of allergic asthma. However, avoid-
ance is sometimes not practical for patients who are
sensitive to house dust mite, and the control of
bronchial inflammation induced by the mite allergens
often requires long-term pharmacotherapy including
inhaled steroids.'
The purpose of this study was to investigate the effect of
IT in asthmatic patients allergic to house dust mite. A
random, double-blind clinical trial would have been the
best investigational approach to this problem. However,
we could not enrol patients in such a trial due to the long
follow-up period and nature of the disease. The clinical
assessment by diary cards was hampered by poor com-
pliance among the children, and most patients reported
few symptoms of asthma exacerbation. Therefore, a
major concern in our open study was to include objective
measurements that were not based on knowledge of the
patient's treatment status.
Pulmonary function test results are an accepted objective
measure of airflow limitation and might be expected to
reflect the clinical status of asthmatic patients. It has long
been known that some pulmonary function abnormalities
may persist after an acute asthmatic attack, and may be
present in cases of asymptomatic asthma. However, it is not
fully known why pulmonary function abnormalities persist in
some patients with asthma who are otherwise free of symp-
toms. In some of these patients, PEF circadian variation has
been proposed as a useful index of asthma stability and
clinical control." We were unable to state authoritatively
why PEF circadian variation decreased with time in most
patients from both groups. Although we suspected that
close clinical follow-up, pharmacotherapy and aging con-
tributed to this trend, we speculated that specific IT might
additionally contribute to lower PEF circadian variation.
Haugaard et 0/. reported that mite-allergic patients
with bronchial asthma who had undergone 2 years of
IT exhibited decreases in both medication and PEF
scores.f Costa et 0/. observed the improvement of PEF
circadian variation in patients with bronchial asthma
after 1 year of IT together with inhaled steroids treat-
ment, although the clinical symptoms were not different
from those of patients treated with inhaled steroids
clone." On the contrary, no amelioration of PEF values
was observed in mite-allergic patients with bronchial
asthma who had undergone specific IT for either
12 rnonths' or 15 months." Unfortunately, however, the
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circadian variations of PEF were not analyzed in either
study. Although the improvements in medication require-
ments were not different statistically between IT-treated
patients and control patients who had not been treated
with IT in this study, Gern et 0/. 16 reported after the
3 year analysis that, in group studies of asthma, medi-
cation usage scores were a less useful indicator of
disease severity than PEF circadian variations.
The improvement of forced expiratory volume in
1 second and FEF2S-7Shas been reported in mite-allergic
patients with bronchial asthma after 1 year of IT. 4 How-
ever, long-term follow-up of the relationship between
specific IT and Vso, V2Sor airway resistance has not been
performed. The present study showed amelioration of
Vsoand V2Safter 3 years of IT in patients with bronchial
asthma. Since Vso and V2S are expected to reflect a
smaller airway function to some degree, it might be
speculated that specific IT makes a therapeutic contri-
bution to inflammatory lesions observed in the smaller
bronchi in patients with bronchial asthma. 18, 19
A study of the microscopic structure of lobar bron-
chial specimens taken from asthmatic patients revealed
airway inflammation with increased numbers of immuno-
modulating cells, including eosinophils, mononuclear
phagocytes and T-helper lymphocytes. 18-2o Various
immunological changes have been reported in mite-
allergic patients receiving specific IT,9-12 but the mecha-
nism underlying its beneficial effect remains largely
unknown. However, several possibilities have been
proposed, including the suppression of an eosinophil
chemotactic factor,9 and monocyte chemotactic and
activating factors produced by mononuclear cells."?
Furthermore, IT has been shown to induce preferential
activation of type 1 T-helper lymphocytes, 12 which down-
regulate the release of allergic inflammatory cytokines
from type 2 T-helper lymphocytes. Because long-term
studies have not proven that pharmacotherapy with
inhaled steroids can impede the decrease in pulmonary
function observed in adult asthmatic patients, the com-
bination of pharmacotherapy and IT is likely to be more
efficacious than pharmacotherapy alone due to the
likely synergistic interference in the inflammatory cas-
cade in the bronchi."
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